MedX Health Corp. said Monday its European pharmacy-focused partner has started a mole-scanning pilot using MedX's SIAscopy technology in 25 United Kingdom Alphega Pharmacies.
The mole-scanning service is based on the successful model in place in 100 Norwegian Boots pharmacies and in a Swedish pharmacy chain where the mole-scanning service has recently grown to 32 locations. This mole-scanning service has identified more than 120 life-threatening melanomas to date.
"This is a positive development for MedX,” MedX CEO Rob von der Porten said. “We will continue to work with our channel partners to support and grow the pharmacy-based direct to consumer application of our technology. We have seen steady sales growth in (the 2nd quarter) and anticipate reporting sound year over year sales gains.”
Alphega Pharmacy is a network of independent pharmacists in Europe that suppots more than 600 pharmacies in the UK, and 6,500 locations across eight European countries. Alphega is part of the Walgreens Boots Alliance.
MedX, headquartered in Mississauga, Ontario, is a medical device company focused on skin cancer. The company manufactures and distributes SIMSYS and MoleMate, hand-held devices that use patented technology to view beneath suspicious moles and lesions.